EUVIMEDEUVIMED entdecken
Crossref

Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment

Huawei Li, Jia You, Yuanfeng Wei, Lingnan Zheng, Ju Yang, Jingyi Xu, Yue Li, Zhaojun Li, Xi Yang, Cheng Yi

Phytomedicine · 2024-01 · 123 · 155189

DOI: 10.1016/j.phymed.2023.155189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024-01. Verfasst von Huawei Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Department of Integrated Traditional C…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Complex Mixtures, Trametes. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Combination therapy is an effective method for augmenting the efficacy of immune checkpoint inhibitors (ICIs). Huaier is a commonly used Chinese patent medicine with substantial antitumor effects. The combination of Huaier and ICIs may increase the efficacy of ICIs against hepatocellular carcinoma (HCC). METHODS: The major components of Huaier were detected by high-performance liquid chromatography-mass spectrometry. The optimal antitumor dose of Huaier was investigated in H22-bearing mice. Next, Huaier was combined with anti-CD8α antibody (Ab) or anti-PD-L1 Ab to observe the antitumor effect. The safety of these combination drugs was evaluated through blood biochemical tests and hematoxylin and eosin staining of histological sections. RT-qPCR, immunohistochemistry, flow cytometry, and transcriptome sequencing were performed to investigate the potential action mechanism of anti-PD-L1 Ab combined with Huaier against HCC. RESULTS: HPLC-MS/MS identified 333 components of Huaier, including carboxylic acids and derivatives, thienothiophenes, phenols, flavonoids and so on. Huaier exhibited significant antitumor effects, with the strongest effect noted at a dose of 4 g/kg. Huaier boosted CD8+ T cells infiltration into the tumor. Next, CD8+ T cells were depleted by with anti-CD8α Ab, and the antitumor effect of Huaier was suppressed. Flow cytometry results revealed that CD8+ T cells were reduced in the Huaier+anti-CD8α Ab group, with the antitumor effect of this group being inhibited. This indicated that CD8+ T cells were key players in the antitumor activity of Huaier. Meanwhile, Huaier inhibited microvessel density (MVD), downregulated vascular endothelial growth factor A (VEGFA), and upregulated PD-L1 in tumor tissues. Finally, Huaier combined with anti-PD-L1 Ab exhibited a greater antitumor effect in the H22-bearing mice. And the results of liver and kidney function tests and histological section analysis unveiled that the safety of these drugs was excellent. According to the transcriptome sequencing results, Huaier combined with anti-PD-L1 Ab possibly exerted anti-HCC effects through immunomodulation, immune response, and so on. CONCLUSIONS: Huaier exhibited a significant antitumor effect. It promoted CD8+ T cells infiltration, upregulated PD-L1 expression, downregulated VEGFA expression, and inhibited MVD, thereby playing a significant antitumor immunoregulatory effect. The combination of Huaier and anti-PD-L1 Ab has significant antitumor effects, and this regimen has good safety. Therefore, Huaier combined with anti-PD-L1 Ab is a promising therapeutic approach against HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsComplex MixturesTrametesAnimalsMiceVascular Endothelial Growth Factor AB7-H1 AntigenCD8-Positive T-LymphocytesTandem Mass SpectrometryCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

Anti-PD-L1 AbCD8(+) T cellsHuaierMVDPD-L1VEGFA

Substanzen

huaierVascular Endothelial Growth Factor AB7-H1 AntigenComplex Mixtures

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Department of Integrated Traditional Chinese and Western Medicine, Cancer Hospital, School of Medicine, Univ…
  • Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
  • West China School of Basic Medical Science and Forensic Medicine, Sichuan University, Chengdu 610041, China.
  • Department of Radiation Oncology, Hainan General Hospital, Haikou 570311, China.
  • Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: yangxi0073@163.com.
  • Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: yicheng6834@126.com.

Zitieren

APA

Li, H., You, J., Wei, Y., Zheng, L., Yang, J., Xu, J., Li, Y., Li, Z., Yang, X., & Yi, C. (2024). Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment. Phytomedicine, 123, 155189. https://doi.org/10.1016/j.phymed.2023.155189

Vancouver

Li H, You J, Wei Y, Zheng L, Yang J, Xu J, et al. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment. Phytomedicine. 2024;123:155189. doi:10.1016/j.phymed.2023.155189

BibTeX
@article{Li2024,
  author = {Li, Huawei and You, Jia and Wei, Yuanfeng and Zheng, Lingnan and Yang, Ju and Xu, Jingyi and Li, Yue and Li, Zhaojun and Yang, Xi and Yi, Cheng},
  title = {Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment},
  journal = {Phytomedicine},
  year = {2024},
  volume = {123},
  pages = {155189},
  doi = {10.1016/j.phymed.2023.155189}
}
Kostenlos starten →